High Risk Patients (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS))
Intermediate Risk Patients (lymphoma regimens and non-leukemia/lymphoma chemotherapy regimens)
Chimeric Antigen Receptor T-cell Therapy (CAR-T) or Tumor-Infiltrating Lymphocyte (TIL)/IL-2 therapy [e.g. lifileucel (Amtagvi)]
Adult Multiple Myeloma and Non-Hodgkin’s Lymphoma Bispecific T-cell Engager Infectious Prophylaxis (e.g. teclistamab)
